Tumor Angiogenesis in Melanoma

Hematology/Oncology Clinics of North America

Volumn 23, Issue 3, 2009, Pages 431-446

  Marneros, Alexander G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Antiangiogenesis; Bone marrow derived cells; Endothelial cells; Melanoma; Vascular endothelial growth factor

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; CARBOPLATIN; CHIR 265; DACARBAZINE; IPILIMUMAB; LOMUSTINE; OXALIPLATIN; PACLITAXEL; PI 88; PLACEBO; RAPAMYCIN; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; B LYMPHOCYTE; BONE MARROW CELL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; CELL POPULATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MEGADOSE; ENDOTHELIUM CELL; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MESENCHYMAL STEM CELL; METASTASIS; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEM CELL; THROMBOEMBOLISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOKINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65649112501     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.03.007     Document Type: Review

References (80)

1. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
2. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
3. Miao W.M., Seng W.L., Duquette M., et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61 (2001) 7830-7839
4. Streit M., Stephen A.E., Hawighorst T., et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 62 (2002) 2004-2012
5. Marneros A.G., and Olsen B.R. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol 20 (2001) 337-345
6. Bergers G., Javaherian K., Lo K.M., et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
7. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
8. Streit M., and Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22 (2003) 3172-3179
9. Skobe M., Hamberg L.M., Hawighorst T., et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 159 (2001) 893-903
10. Salven P., Lymboussaki A., Heikkila P., et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153 (1998) 103-108
11. He Y., Rajantie I., Ilmonen M., et al. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64 (2004) 3737-3740
12. Dadras S.S., Paul T., Bertoncini J., et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162 (2003) 1951-1960
13. Hirakawa S., Kodama S., Kunstfeld R., et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201 (2005) 1089-1099
14. Hirakawa S., Brown L.F., Kodama S., et al. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109 (2007) 1010-1017
15. Brychtova S., Bezdekova M., Brychta T., et al. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 55 (2008) 273-279
16. Lacal P.M., Failla C.M., Pagani E., et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115 (2000) 1000-1007
17. Lacal P.M., Ruffini F., Pagani E., et al. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 27 (2005) 1625-1632
18. Reed J.A., McNutt N.S., and Albino A.P. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 144 (1994) 329-336
19. Giehl K.A., Nagele U., Volkenandt M., et al. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol 34 (2007) 7-14
20. Nurnberg W., Tobias D., Otto F., et al. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 189 (1999) 546-551
21. Barnhill R.L., Xiao M., Graves D., et al. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 135 (1996) 898-904
22. Westermark B., Johnsson A., Paulsson Y., et al. Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A 83 (1986) 7197-7200
23. Nozawa H., Chiu C., and Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103 (2006) 12493-12498
24. Ardi V.C., Kupriyanova T.A., Deryugina E.I., et al. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A 104 (2007) 20262-20267
25. Conejo-Garcia J.R., Benencia F., Courreges M.C., et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10 (2004) 950-958
26. Yang L., DeBusk L.M., Fukuda K., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004) 409-421
27. Heissig B., Hattori K., Dias S., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 (2002) 625-637
28. Shojaei F., Wu X., Malik A.K., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25 (2007) 911-920
29. LeCouter J., Zlot C., Tejada M., et al. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A 101 (2004) 16813-16818
30. Jin D.K., Shido K., Kopp H.G., et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12 (2006) 557-567
31. Mohle R., Green D., Moore M.A., et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94 (1997) 663-668
32. Italiano Jr. J.E., Richardson J.L., Patel-Hett S., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111 (2008) 1227-1233
33. Kopp H.G., Hooper A.T., Broekman M.J., et al. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest 116 (2006) 3277-3291
34. Klement G.L., Yip T.T., Cassiola F., et al. Platelets actively sequester angiogenesis regulators. Blood (2008)
35. Du R., Lu K.V., Petritsch C., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008) 206-220
36. Sipkins D.A., Wei X., Wu J.W., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435 (2005) 969-973
37. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
38. Murakami T., Cardones A.R., Finkelstein S.E., et al. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 198 (2003) 1337-1347
39. Gunn M.D., Tangemann K., Tam C., et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 95 (1998) 258-263
40. Saeki H., Moore A.M., Brown M.J., et al. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 162 (1999) 2472-2475
41. Peters B.A., Diaz L.A., Polyak K., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11 (2005) 261-262
42. Purhonen S., Palm J., Rossi D., et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A 105 (2008) 6620-6625
43. Gao D., Nolan D.J., Mellick A.S., et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319 (2008) 195-198
44. Nolan D.J., Ciarrocchi A., Mellick A.S., et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 21 (2007) 1546-1558
45. Hirschi K.K., Ingram D.A., and Yoder M.C. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28 (2008) 1584-1595
46. Lyden D., Young A.Z., Zagzag D., et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401 (1999) 670-677
47. Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7 (2001) 1194-1201
48. Hattori K., Dias S., Heissig B., et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193 (2001) 1005-1014
49. Grunewald M., Avraham I., Dor Y., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
50. Greenberg J.I., Shields D.J., Barillas S.G., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456 (2008) 809-813
51. Stockmann C., Doedens A., Weidemann A., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456 (2008) 814-818
52. Xian X., Hakansson J., Stahlberg A., et al. Pericytes limit tumor cell metastasis. J Clin Invest 116 (2006) 642-651
53. Song S., Ewald A.J., Stallcup W., et al. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7 (2005) 870-879
54. Crisan M., Yap S., Casteilla L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3 (2008) 301-313
55. Karnoub A.E., Dash A.B., Vo A.P., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (2007) 557-563
56. Hillyer P., and Male D. Expression of chemokines on the surface of different human endothelia. Immunol Cell Biol 83 (2005) 375-382
57. Rajantie I., Ilmonen M., Alminaite A., et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104 (2004) 2084-2086
58. Bexell D., Gunnarsson S., Tormin A., et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 17 1 (2009) 183-190
59. Studeny M., Marini F.C., Champlin R.E., et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62 (2002) 3603-3608
60. Ren C., Kumar S., Chanda D., et al. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 26 (2008) 2332-2338
61. Elzaouk L., Moelling K., and Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 15 (2006) 865-874
62. McAllister S.S., Gifford A.M., Greiner A.L., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133 (2008) 994-1005
63. Rangel J., Nosrati M., Torabian S., et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer 112 (2008) 144-150
64. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
65. Hiratsuka S., Watanabe A., Aburatani H., et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8 (2006) 1369-1375
66. Hiratsuka S., Watanabe A., Sakurai Y., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10 (2008) 1349-1355
67. Peinado H., Rafii S., and Lyden D. Inflammation joins the "niche". Cancer Cell 14 (2008) 347-349
68. Wels J., Kaplan R.N., Rafii S., et al. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 22 (2008) 559-574
69. Orimo A., Gupta P.B., Sgroi D.C., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005) 335-348
70. Sun J., Blaskovich M.A., Jain R.K., et al. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 64 (2004) 3586-3592
71. Molhoek K.R., Griesemann H., Shu J., et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 68 (2008) 4392-4397
72. Jaissle G.B., Ulmer A., Henke-Fahle S., et al. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 144 (2008) 525-527
73. Kurzen H., Schmitt S., Naher H., et al. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14 (2003) 515-522
74. Lev D.C., Ruiz M., Mills L., et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2 (2003) 753-763
75. Varker K.A., Biber J.E., Kefauver C., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14 (2007) 2367-2376
76. Yuan J., Gnjatic S., Li H., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105 51 (2008) 20410-20415
77. Krown S.E., Niedzwiecki D., Hwu W.J., et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107 (2006) 1883-1890
78. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
79. Egberts F., Kahler K.C., Livingstone E., et al. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie 31 (2008) 398-403
80. McDermott D.F., Sosman J.A., Gonzalez R., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26 (2008) 2178-2185